about
Environmental factors and their regulation of immunity in multiple sclerosisTreatment of seizures in multiple sclerosisReproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patientsQuetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair.Jerking & confused: Leucine-rich glioma inactivated 1 receptor encephalitis.Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance.Reduced creatine kinase B activity in multiple sclerosis normal appearing white matterCardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.Uric acid in multiple sclerosis.Therapeutic potential of fluoxetine in neurological disorders.Incidence and prevalence of multiple sclerosis in Europe: a systematic reviewLong-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort studyAn inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.Plasma homocysteine levels in multiple sclerosis.Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders.Epigenetics and miRNAs in the diagnosis and treatment of multiple sclerosis.Incidence and prevalence of multiple sclerosis in the Americas: a systematic review.The promise of futility trials in neurological diseases.MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review.Serum NSE level and disability progression in multiple sclerosis.Validity of four screening scales for major depression in MS.Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis.Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study.Depression in multiple sclerosis: a long-term longitudinal study.Parity and secondary progression in multiple sclerosis.A fatal demyelinating illness in a young woman 10 weeks post partum.Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke.Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis.Global transcriptome profiling of mild relapsing remitting versus primary progressive Multiple Sclerosis.Cerebral white matter blood flow and energy metabolism in multiple sclerosis.Smoking does not influence disability accumulation in primary progressive multiple sclerosis.Plasma lipid peroxidation and progression of disability in multiple sclerosis.Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.The natural history of early versus late disability accumulation in primary progressive MS.Hand dexterity and direct disease related cost in multiple sclerosis.Performance on Paced Auditory Serial Addition Test and cerebral blood flow in multiple sclerosis.Primary and secondary progressive MS have a similar age at onset of progression - Commentary.The natural history of primary progressive multiple sclerosis.
P50
Q22252381-F23CAA7A-1CF5-42C8-A09A-C9DCA36D6564Q24239977-D21551CB-3ECD-4A07-A1AD-9803DE3D5C65Q24657825-95574697-A346-4B84-B327-40EE6014A8D5Q30656233-D1A59BFC-6735-49BA-A60A-0B4C5583CAB6Q31029209-1BE78DED-31B3-4F99-A8C2-4712CDACBCCFQ31161124-E98FECF0-B3C6-4D0D-BD51-069F02752464Q33593127-69D0F3A2-3A37-45F4-9595-F66A0C6FDAB5Q33593127-A32D171B-BA4A-4BC9-9E9E-969568ECD8CCQ33899881-E1D9B31D-9D06-4FC7-80F4-1E050A1758B9Q34523966-BDD0A90F-0504-4126-94C7-FC265406F30DQ34778793-C06AFF3E-AE53-4363-BB03-4DDD947A2FEDQ35000110-6A447342-79B2-4B12-B99B-50D00CEF0B55Q35388991-87CBCEF6-740B-4A7C-AF0D-2F7B7D7A19FEQ35999574-4E24247F-C5AE-41D6-BA45-58CBB1D803A4Q36142503-29CC9B56-A2AC-4E03-BABD-312A39DDC46DQ36970752-1571E86F-E5E5-4439-82B3-1525598CA10DQ38059937-4B750822-08BE-42FA-84D9-A9CAF08694B1Q38077875-7929AE6F-F595-44C2-99EC-967F6FA2D85DQ38380170-82319507-25CF-419E-81F4-30F5249FF107Q38422894-693BFB39-9DEA-4E91-BB05-CCE326329B4FQ41428700-42844B16-F572-4061-9E15-A95472F8785EQ41589787-E8CEA980-A15B-49DD-8EF4-5CC16638611BQ41916874-EE43BC2B-54F9-4B9A-B6D7-56AD861C73CEQ43575338-A7687AF5-F5D9-4FA0-8B07-4A28B154516EQ43578696-9578D2B6-390E-4AEA-83CD-D694C05EE182Q44007125-0B7A3CF9-0CBC-4D5A-BB52-4E2BBB8CB7AFQ44081468-C0EF19F5-B72D-4597-903E-45ACDD75DAEBQ45010207-C8E9B20B-3DAC-4447-966E-7050F8E7336AQ45233964-A552B140-32FB-4016-9B86-A79C668A2EA7Q46704364-99301352-830D-45C6-B106-BBB246A11A79Q46945547-6D2FF27F-1248-4FA1-A3ED-CEF2BAA97033Q47874571-A079AFCC-EB61-42F3-B3A5-AE18DBB8B182Q48154258-F53EAE05-9797-4048-8FE3-6B302B4B5633Q48192322-245410C3-6E87-49D6-B979-7434A7494022Q48201059-04E86178-6C19-4EED-ABE8-1092ED4AADDEQ48219895-DF885068-FC8C-4350-A807-B57D75EE5EC6Q48621435-50BDF315-0A96-4FEC-ACA0-F67F669639F6Q50051901-91A01E05-F43F-4B8D-8B7E-80C6CB1C1459Q50906773-BB5F2F57-3A07-48E5-A43E-262E7AD93B06Q54212862-300A7881-759F-4B61-A6E3-0DD6885173B5
P50
description
researcher ORCID ID = 0000-0001-9972-5092
@en
wetenschapper
@nl
name
Marcus W Koch
@ast
Marcus W Koch
@en
Marcus W Koch
@es
Marcus W Koch
@nl
type
label
Marcus W Koch
@ast
Marcus W Koch
@en
Marcus W Koch
@es
Marcus W Koch
@nl
prefLabel
Marcus W Koch
@ast
Marcus W Koch
@en
Marcus W Koch
@es
Marcus W Koch
@nl
P108
P106
P1153
8977781800
P31
P496
0000-0001-9972-5092